

Collaborative Staging Codes
Broad and Round Ligaments, Parametrium, Uterine Adnexa
C57.1-C57.4

C57.1 Broad ligament
 C57.2 Round ligament
 C57.3 Parametrium
 C57.4 Uterine adnexa

Note: AJCC does not define TNM staging for this site.

CS Tumor Size	CS Site-Specific Factor 1	The following tables are available at the collaborative staging website: Histologies for Which AJCC Staging Is Not Generated AJCC Stage
CS Extension	CS Site-Specific Factor 2	
CS TS/Ext-Eval	CS Site-Specific Factor 3	
CS Lymph Nodes	CS Site-Specific Factor 4	
CS Reg Nodes Eval	CS Site-Specific Factor 5	
Reg LN Pos	CS Site-Specific Factor 6	
Reg LN Exam		
CS Mets at DX		
CS Mets Eval		

Broad and Round Ligaments, Parametrium, Uterine Adnexa
CS Tumor Size
SEE STANDARD TABLE

Broad and Round Ligaments, Parametrium, Uterine Adnexa
CS Extension

Code	Description	TNM	SS77	SS2000
00	In situ; non-invasive; intraepithelial	NA	IS	IS
10	Confined to tissue or organ of origin	NA	L	L
30	Localized, NOS	NA	L	L
40	Corpus uteri Ovary, ipsilateral Uterus, NOS	NA	RE	RE
50	Fallopian tube for ligaments Mesosalpinx, ipsilateral Peritoneum	NA	RE	RE
70	Cervix uteri Cul de sac (rectouterine pouch) Omentum Ovary, contralateral Rectosigmoid Sigmoid Small intestine	NA	D	D
80	Further contiguous extension	NA	D	D
95	No evidence of primary tumor	NA	U	U
99	Unknown extension Primary tumor cannot be assessed Not documented in patient record	NA	U	U

**Broad and Round Ligaments, Parametrium, Uterine Adnexa
CS TS/Ext-Eval**

Code	Description	Staging Basis
9	Not applicable for this site	NA

**Broad and Round Ligaments, Parametrium, Uterine Adnexa
CS Lymph Nodes**

Note: Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in the field Mets at DX.

Code	Description	TNM	SS77	SS2000
00	None; no regional lymph node involvement	NA	NONE	NONE
10	Regional lymph node(s): Aortic, NOS: Lateral (lumbar) Para-aortic Periaortic Iliac, NOS: Common External Internal (hypogastric): Obturator Inguinal Lateral sacral (laterosacral) Pelvic, NOS Retroperitoneal, NOS Regional lymph node(s), NOS	NA	RN	RN
80	Lymph nodes, NOS	NA	RN	RN
99	Unknown; not stated Regional lymph node(s) cannot be assessed Not documented in patient record	NA	U	U

**Broad and Round Ligaments, Parametrium, Uterine Adnexa
CS Reg Nodes Eval**

Code	Description	Staging Basis
9	Not applicable for this site	NA

**Broad and Round Ligaments, Parametrium, Uterine Adnexa
Reg LN Pos
SEE STANDARD TABLE**

**Broad and Round Ligaments, Parametrium, Uterine Adnexa
Reg LN Exam
SEE STANDARD TABLE**

**Broad and Round Ligaments, Parametrium, Uterine Adnexa
CS Mets at DX**

Code	Description	TNM	SS77	SS2000
00	No; none	NA	NONE	NONE
10	Distant lymph node(s), NOS	NA	D	D
40	Distant metastases except distant lymph node(s) (code 10) Distant metastasis, NOS Carcinomatosis	NA	D	D
50	(10) + (40) Distant lymph node(s) plus other distant metastases	NA	D	D
99	Unknown if distant metastasis Cannot be assessed Not documented in patient record	NA	U	U

**Broad and Round Ligaments, Parametrium, Uterine Adnexa
CS Mets Eval**

Code	Description	Staging Basis
9	Not applicable for this site	NA

**Broad and Round Ligaments, Parametrium, Uterine Adnexa
CS Site-Specific Factor 1**

Code	Description
888	Not applicable for this site

**Broad and Round Ligaments, Parametrium, Uterine Adnexa
CS Site-Specific Factor 2**

Code	Description
888	Not applicable for this site

**Broad and Round Ligaments, Parametrium, Uterine Adnexa
CS Site-Specific Factor 3**

Code	Description
888	Not applicable for this site

**Broad and Round Ligaments, Parametrium, Uterine Adnexa
CS Site-Specific Factor 4**

Code	Description
888	Not applicable for this site

**Broad and Round Ligaments, Parametrium, Uterine Adnexa
CS Site-Specific Factor 5**

Code	Description
888	Not applicable for this site

**Broad and Round Ligaments, Parametrium, Uterine Adnexa
CS Site-Specific Factor 6**

Code	Description
888	Not applicable for this site

Collaborative Staging Codes
Other and Unspecified Female Genital Organs
C57.7-C57.9

C57.7 Other specified parts of female genital organs

C57.8 Overlapping lesion of female genital organs

C57.9 Female genital tract, NOS

Note: AJCC does not define TNM staging for this site.

CS Tumor Size	CS Site-Specific Factor 1	The following tables are available at the collaborative staging website: Histologies for Which AJCC Staging Is Not Generated AJCC Stage
CS Extension	CS Site-Specific Factor 2	
CS TS/Ext-Eval	CS Site-Specific Factor 3	
CS Lymph Nodes	CS Site-Specific Factor 4	
CS Reg Nodes Eval	CS Site-Specific Factor 5	
Reg LN Pos	CS Site-Specific Factor 6	
Reg LN Exam		
CS Mets at DX		
CS Mets Eval		

Other and Unspecified Female Genital Organs

CS Tumor Size

SEE STANDARD TABLE

Other and Unspecified Female Genital Organs

CS Extension

Code	Description	TNM	SS77	SS2000
00	In situ; non-invasive; intraepithelial	NA	IS	IS
10	Confined to site of origin	NA	L	L
30	Localized, NOS	NA	L	L
40	Adjacent connective tissue (See definition in General Instructions)	NA	RE	RE
60	Adjacent organs/structures: Female genital organs: Adnexa Broad ligament(s) Cervix uteri Corpus uteri Fallopian tube(s) Ovary(ies) Parametrium Round ligament(s) Uterus, NOS Vagina	NA	RE	RE
80	Further contiguous extension: Other organs of pelvis	NA	D	D
95	No evidence of primary tumor	NA	U	U
99	Unknown extension Primary tumor cannot be assessed Not documented in patient record	NA	U	U

**Other and Unspecified Female Genital Organs
CS TS/Ext-Eval**

Code	Description	Staging Basis
9	Not applicable for this site	NA

**Other and Unspecified Female Genital Organs
CS Lymph Nodes**

Note: Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in the field Mets at DX.

Code	Description	TNM	SS77	SS2000
00	No regional lymph node involvement	NA	NONE	NONE
10	Regional lymph node(s), NOS	NA	RN	RN
80	Lymph nodes, NOS	NA	RN	RN
99	Unknown; not stated Regional lymph node(s) cannot be assessed Not documented in patient record	NA	U	U

**Other and Unspecified Female Genital Organs
CS Reg Nodes Eval**

Code	Description	Staging Basis
9	Not applicable for this site	NA

**Other and Unspecified Female Genital Organs
Reg LN Pos
SEE STANDARD TABLE**

**Other and Unspecified Female Genital Organs
Reg LN Exam
SEE STANDARD TABLE**

**Other and Unspecified Female Genital Organs
CS Mets at DX**

Code	Description	TNM	SS77	SS2000
00	No; none	NA	NONE	NONE
10	Distant lymph node(s), NOS	NA	D	D
40	Distant metastases except distant lymph node(s) (code 10) Distant metastasis, NOS Carcinomatosis	NA	D	D
50	(10) + (40) Distant lymph node(s) plus other distant metastases	NA	D	D

99	Unknown if distant metastasis Cannot be assessed Not documented in patient record	NA	U	U
----	---	----	---	---

Other and Unspecified Female Genital Organs

CS Mets Eval

Code	Description	Staging Basis
9	Not applicable for this site	NA

Other and Unspecified Female Genital Organs

CS Site-Specific Factor 1

Code	Description
888	Not applicable for this site

Other and Unspecified Female Genital Organs

CS Site-Specific Factor 2

Code	Description
888	Not applicable for this site

Other and Unspecified Female Genital Organs

CS Site-Specific Factor 3

Code	Description
888	Not applicable for this site

Other and Unspecified Female Genital Organs

CS Site-Specific Factor 4

Code	Description
888	Not applicable for this site

Other and Unspecified Female Genital Organs

CS Site-Specific Factor 5

Code	Description
888	Not applicable for this site

Other and Unspecified Female Genital Organs

CS Site-Specific Factor 6

Code	Description
888	Not applicable for this site

Page intentionally blank

Collaborative Staging Codes

Placenta

C58.9

C58.9 Placenta

Note 1: This schema correlates to the AJCC's Gestational Trophoblastic Tumors scheme. In most cases, gestational trophoblastic tumors (ICD-O-3 morphology codes 9100-9105) are coded to placenta, C58.9.

Note 2: If a trophoblastic tumor is not associated with a pregnancy and arises in another site, such as ovary, use the primary site code and Collaborative Staging schema for that site.

CS Tumor Size	CS Site-Specific Factor 1 -	The following tables are available at the collaborative staging website: Histology Exclusion Table AJCC Stage
CS Extension	Prognostic Scoring Index Table 1	
CS TS/Ext-Eval	CS Site-Specific Factor 2	
CS Lymph Nodes	CS Site-Specific Factor 3	
Reg Nodes Eval	CS Site-Specific Factor 4	
Reg LN Pos	CS Site-Specific Factor 5	
Reg LN Exam	CS Site-Specific Factor 6	
CS Mets at DX		
CS Mets Eval		

Placenta

CS Tumor Size

SEE STANDARD TABLE

Placenta

CS Extension

Note 1: Substaging of gestational trophoblastic tumors are determined by the value coded in the Prognostic Scoring Index Table, using Site Specific Factor 1. See note in Site Specific Factor 1, Prognostic Index Table to determine the prognostic index score.

Note 2: For this schema, according to AJCC, involvement of genital structures may be either by direct extension or metastasis and is still T2. For Collaborative Staging, metastasis to genital structures should be coded 70 in CS Extension and not coded in CS Mets at DX.

Code	Description	TNM	SS77	SS2000
00	In situ: Noninvasive; intraepithelial FIGO Stage 0	Tis	IS	IS
10	Confined to placenta FIGO Stage I	T1	L	L
30	Localized, NOS FIGO Stage 1	T1	L	L
40	Adjacent connective tissue, NOS FIGO Stage II	T2	RE	RE
60	Other genital structures by direct extension or NOS: Broad ligament Cervix Corpus uteri Fallopian tube(s) Genital structures, NOS Ovary(ies) Uterus, NOS Vagina FIGO Stage II	T2	RE	RE

70	Other genital structures, by metastasis: Broad ligament Cervix Corpus uteri Fallopian tube(s) Genital structures, NOS Ovary(ies) Uterus, NOS Vagina FIGO Stage II	T2	D	D
80	Further contiguous extension	T4	D	D
95	No evidence of primary tumor	T0	U	U
99	Unknown extension Primary tumor cannot be assessed Not documented in patient record	TX	U	U

Note: For codes 10 - 80, the substaging is determined by using the Risk Scores in the Prognostic Scoring Index in Site Specific Factor 1 Table.

**Placenta
CS TS/Ext-Eval
SEE STANDARD TABLE**

**Placenta
CS Lymph Nodes**

Code	Description	TNM	SS77	SS2000
88	Not applicable	NA	U	U

**Placenta
Reg Nodes Eval**

Code	Description	
9	Does not apply	NA

**Placenta
Reg LN Pos**

Code	Description
99	Does not apply

**Placenta
Reg LN Exam**

Code	Description
99	Does not apply

Placenta

CS Mets at DX

Note 1: All lymph node involvement is considered M1 in TNM, so all lymph node involvement, whether regional or distant nodes, is coded in the field Mets at DX.

Note 2: According to AJCC, metastasis to genital structures is considered T2 and not M1 for GTT. For this Collaborative Staging schema, metastasis to genital structures is coded 70 in CS Extension and not coded in CS Mets at DX.

Code	Description	TNM	SS77	SS2000
00	No; none	M0	NONE	NONE
10	Metastasis to lung(s) only, NOS FIGO III	M1a	D	D
20	Regional lymph nodes: Iliac, NOS: Common External Internal (hypogastric), NOS Obturator Parametrial Pelvic, NOS Sacral, NOS: Lateral Presacral Promontory (Gerota's) Uterosacral	M1b	RN	RN
30	Regional lymph nodes: Aortic, NOS: Lateral Para-aortic Periaortic	M1b	RN	RN
35	(20) + (30)	M1b	RN	RN
40	Regional lymph node(s), NOS	M1b	RN	RN
50	Distant lymph node(s), NOS	M1b	D	D
51	Distant lymph node(s): Superficial inguinal (femoral)	M1b	D	D
52	Specified distant lymph node(s) other than in code 51	M1b	D	D
60	Lymph nodes, NOS	M1b	D	D
70	Distant metastases, other than lymph node(s) or lung Distant metastasis, NOS Carcinomatosis	M1b	D	D
80	(70) + any of [(10) to (60)]	M1b	D	D
99	Unknown Distant metastasis cannot be assessed Not documented in patient record	MX	U	U

Placenta
CS Mets Eval
SEE STANDARD TABLE

Placenta
CS Site-Specific Factor 1 Prognostic Scoring Index Table 1

Note: Clinician scoring is recommended. If any one of the factors is unknown, stop trying to assign score, unless you have already determined with the factors you have - low risk or high risk. The score on the Prognostic Scoring Index is used to substage patients. Substage A (low risk) and Substage B (high risk) are assigned on the basis of a non-anatomic risk factor scoring system:

- AGE [Score 0: age less than or equal to 40; Score 1: age 40 or more]
- ANTECEDENT PREG [Score 0: Hydatidiform mole; Score 1: Abortion; Score 2: Term pregnancy]
- MONTHS FROM INDEX PREG [Score 0: less than 4; Score 1: 4 months and less than 7 months; Score 2: 7 months to 12 months; Score 4: More than 12 months]
- PRETREATMENT SERUM hCG(IU/ml) [Score 0: <10 to 3rd power, (1,000); Score 1: 10-3rd power to 10-4th power (1,000 to less than 10,000); Score 2: 10-4th power to less than 10-5th power (10,000 to less than 100,000); Score 4: greater than or equal to 10-5th power (100,000 or greater)]
- LARGEST TUMOR SIZE, INCLUDING UTERUS [Score 0: < 3 cm; Score 1: 3-<5 cm; Score 2: greater than or equal to 5 cm]
- SITES OF METS [Score 0: Lung only or None; Score 1: Spleen, kidney; Score 2: Gastrointestinal tract; Score 4: Liver, brain]
- NUMBER OF METS [Score 0: 0; Score 1: 1-4; Score 2: 5-8; Score 4: >8]
- PREVIOUS FAILED CHEMOTHERAPY [Score 2: Single drug; Score 4: 2 or more drugs]. Sum the score of each prognostic risk factor(s) to determine the final Prognostic Scoring Index in the table below:

Code	Description
000	Clinician stated no risk factors
001	Clinician stated low risk (sum score of 7 or less) Stated to be substage A, but score not specified
002	Clinician stated high risk (sum score of 8 or greater or NOS) Stated to be substage B, but score not specified
200	Clinician stated to have risk factors, but unknown whether low or high risk.
999	Unknown Risk factors cannot be assessed Not documented in patient record

Placenta
CS Site-Specific Factor 2

Code	Description
888	Not applicable for this site

Placenta
CS Site-Specific Factor 3

Code	Description
888	Not applicable for this site

Placenta

CS Site-Specific Factor 4

Code	Description
888	Not applicable for this site

Placenta

CS Site-Specific Factor 5

Code	Description
888	Not applicable for this site

Placenta

CS Site-Specific Factor 6

Code	Description
888	Not applicable for this site

Collaborative Staging Codes

Penis [excl Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease and Other Lymphomas]

C60.0-C60.2, C60.8-C60.9

C60.0 Prepuce

C60.1 Glans penis

C60.2 Body of penis

C60.8 Overlapping lesion of penis

C60.9 Penis, NOS

Note: This schema is NOT used for Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease, or Other Lymphomas. Each of these diseases has a separate schema.

CS Tumor Size	CS Site-Specific Factor 1	The following tables are available at the collaborative staging website: Histology Exclusion Table AJCC Stage
CS Extension	CS Site-Specific Factor 2	
CS TS/Ext-Eval	CS Site-Specific Factor 3	
CS Lymph Nodes	CS Site-Specific Factor 4	
CS Reg Nodes Eval	CS Site-Specific Factor 5	
Reg LN Pos	CS Site-Specific Factor 6	
Reg LN Exam		
CS Mets at DX		
CS Mets Eval		

Penis [excl Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease and Other Lymphomas]

CS Tumor Size

SEE STANDARD TABLE

Penis [excl Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease and Other Lymphomas]

CS Extension

Code	Description	TNM	SS77	SS2000
00	In situ: noninvasive; Bowen disease; intraepithelial	Tis	IS	IS
05	Noninvasive verrucous carcinoma	Ta	IS	IS
10	Invasive tumor limited to subepithelial connective tissue, but not involving corpus spongiosum or cavernosum If primary is skin: invasive tumor limited to skin of penis, prepuce (foreskin) and/or glans	T1	L	L
30	Localized, NOS	T1	L	L
35	For body of penis ONLY: Corpus cavernosum Corpus spongiosum Tunica albuginea of corpus spongiosum	T2	L	L
40	Corpus cavernosum except for tumor in body of penis Corpus spongiosum except for tumor in body of penis Tunica albuginea of corpus spongiosum except for tumor in body of penis	T2	RE	RE
50	Satellite nodule(s) on prepuce or glans	T1	RE	RE

60	Urethra Prostate	T3	RE	RE
70	Adjacent structures: Muscle, NOS: Bulbospongiosus Ischiocavernosus Superficial transverse perineal Skin: Abdominal Perineum Pubic Scrotal	T4	RE	RE
80	Further contiguous extension Testis	T4	D	D
95	No evidence of primary tumor	T0	U	U
99	Unknown extension Primary tumor cannot be assessed Not documented in patient record	TX	U	U

Penis [excl Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease and Other Lymphomas]

CS TS/Ext-Eval

SEE STANDARD TABLE

Penis [excl Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease and Other Lymphomas]

CS Lymph Nodes

Note 1: Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in the field Mets at DX.

Note 2: If the clinician says "adnexa palpated" but doesn't mention lymph nodes, assume lymph nodes are not involved.

Note 3: If either exploratory/definitive surgery is done with no mention of lymph nodes, assume nodes are negative.

Code	Description	TNM	SS77	SS2000
00	No regional lymph node involvement	N0	NONE	NONE
10	SINGLE superficial inguinal (femoral) regional lymph node	N1	RN	RN
20	Multiple OR bilateral superficial inguinal (femoral) regional lymph nodes	N2	RN	RN
30	Regional lymph nodes: Deep inguinal, NOS: Node of Cloquet or Rosenmuller (highest deep inguinal)	N3	RN	RN
40	Regional lymph nodes: External iliac Internal iliac (hypogastric) Obturator Pelvic nodes, NOS	N3	RN	RN
50	Regional Lymph Node(s), NOS	N1	RN	RN

80	Lymph nodes, NOS	N1	RN	RN
99	Unknown; not stated Regional lymph node(s) cannot be assessed Not documented in patient record	NX	U	U

**Penis [excl Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease and Other Lymphomas]
CS Reg Nodes Eval
SEE STANDARD TABLE**

**Penis [excl Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease and Other Lymphomas]
Reg LN Pos
SEE STANDARD TABLE**

**Penis [excl Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease and Other Lymphomas]
Reg LN Exam
SEE STANDARD TABLE**

**Penis [excl Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease and Other Lymphomas]
CS Mets at DX
SEE STANDARD TABLE**

**Penis [excl Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease and Other Lymphomas]
CS Mets Eval
SEE STANDARD TABLE**

**Penis [excl Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease and Other Lymphomas]
CS Site-Specific Factor 1**

Code	Description
888	Not applicable for this site

**Penis [excl Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease and Other Lymphomas]
CS Site-Specific Factor 2**

Code	Description
888	Not applicable for this site

Penis [excl Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease and Other Lymphomas]

CS Site-Specific Factor 3

Code	Description
888	Not applicable for this site

Penis [excl Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease and Other Lymphomas]

CS Site-Specific Factor 4

Code	Description
888	Not applicable for this site

Penis [excl Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease and Other Lymphomas]

CS Site-Specific Factor 5

Code	Description
888	Not applicable for this site

Penis [excl Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease and Other Lymphomas]

CS Site-Specific Factor 6

Code	Description
888	Not applicable for this site

Page intentionally blank

PROSTATE C619

Priority Rules for Grading Prostate Cancer

Code the tumor grade using the following priority order.

1. Gleason's grade (Use the table to convert Gleason's grade information into the appropriate code)
2. Terminology
Differentiation (well differentiated, moderately differentiated, etc)
3. Histologic grade
Grade i, grade ii, grade iii, grade iv
4. Nuclear grade only

Gleason's Pattern

Prostate cancers are commonly graded using Gleason's score or pattern. Gleason's grading is based on a 5-component system, meaning it is based on 5 histologic patterns. The pathologist will evaluate the primary (majority) and secondary patterns for the tumor. The pattern is written as a range, with the majority pattern appearing first and the secondary pattern as the last number

Example: A Gleason pattern of 2 + 4 means that the primary pattern is 2 and the secondary pattern is 4.

Gleason's Score

The patterns are added together to create a score.

Example: If the pattern is 2 + 4, the pattern score is 6 (the sum of 2 and 4).

1. If the pathology report contains only **one number**, and that number is **less than or equal to 5**, it is a pattern.
2. If the pathology report contains only **one number**, and that number is **greater than 5**, it is a score.
3. If the pathology report specifies a specific **number out of a total of 10**, the first number given is the score.

Example: The pathology report says "Gleason's 3/10". The Gleason's score would be 3.

4. If there are **two numbers other than 10**, assume they refer to two patterns. The first number is the primary pattern and the second is the secondary pattern.

Example: If the pathology report says "Gleason's 3 + 5," the Gleason's score would be 8, the sum of 3 and 5.

Use the following table to convert Gleason's pattern or score into SEER codes:

Gleason Conversion Table

Gleason's Score	Gleason's Pattern	Histologic Grade	Terminology	SEER Code
2, 3, 4	1, 2	I	Well differentiated	1
5, 6	3	II	Moderately differentiated	2
7, 8, 9, 10	4, 5	III	Poorly differentiated	3

Note: Code 7 was moved from Moderately differentiated to Poorly differentiated with cases diagnosed in 01/01/2003.

Collaborative Staging Codes

Prostate

C61.9

C61.9 Prostate gland

Note: Transitional cell carcinoma of the prostatic urethra is to be coded to primary site C68.0, Urethra, and assigned Collaborative Stage codes according to the urethra scheme.

CS Tumor Size	CS Site-Specific Factor 1 - Prostatic Specific Antigen (PSA) Lab Value	The following tables are available at the collaborative staging website: Histologies for Which AJCC Staging is not Generated AJCC Stage for TNM Sites with no stage groupings.
CS Extension	CS Site-Specific Factor 2 - Prostatic Specific Antigen (PSA)	
CS TS/Ext-Eval	CS Site-Specific Factor 3 - CS Extension - Pathologic Extension	
CS Lymph Nodes	CS Site-Specific Factor 4 - Prostatic Acid Phosphatase (PAP)	
CS Lymph Nodes Eval	CS Site-Specific Factor 5 - Gleason's Primary Pattern and Secondary Pattern Value	
Reg LN Pos	CS Site-Specific Factor 6 - Gleason's Score	
Reg LN Exam		
CS Mets at DX		
CS Mets Eval		

Prostate

CS Tumor Size

SEE STANDARD TABLE

Prostate

CS Extension-Clinical Extension

Note 1: This field and Site-Specific Factor 3, CS Extension - Pathologic Extension, must both be coded, whether or not a prostatectomy is EXCLUDED from this field and coded only in Site-Specific Factor 3.

Note 2:

A. Codes 10-15: 1) CODES 10 to 15 are used only for clinically inapparent tumor not palpable or visible by imaging and incidentally found microscopic carcinoma (latent, occult) in one or both lobes. Within this range, give priority to codes 13-15 over code 10. 2) When tumor is found in one lobe or in both lobes by needle biopsy but is not palpable or visible by imaging, use code 15.

B. CODES 20 to 24 are used only for clinically/radiographically apparent tumor, i.e., that which is palpable or visible by imaging. Codes 21 and 22 have precedence over code 20. Code 20 has precedence over code 24.

C. CODE 30 is used for localized cancer when it is unknown if clinically or radiographically apparent. An example would be when a diagnosis is made prior to admission for a prostatectomy with no details provided on clinical findings prior to admission.

D. CODES 33 and 34 have precedence over code 31.

E. CODES 41 to 49 are used for extension beyond the prostate.

Note 3: Use codes 13-14 when a TURP is done, not for a biopsy only. Do not use code 15 when a TURP is done.

Note 4: Involvement of the prostatic urethra does not alter the extension code.

Note 5: "Frozen pelvis" is a clinical term which means tumor extends to pelvic sidewall(s). In the absence of a more detailed statement of involvement, assign this to code 60.

Note 6: AUA stage. Some of the American Urological Association (AUA) stages A-D are provided as guidelines for coding in the absence of more specific information in the medical record. If physician-assigned AUA stage D1-D2 is based on involvement of lymph nodes only, code under CS Lymph Nodes or CS Mets at DX, not CS Extension.

Note 7: This schema includes evaluation of other pathologic tissue such as a biopsy of the rectum.

Note 8: For this site, the T category and its associated c, p, y, or an indicator are assigned based on the values in CS Extension, CS TS/Ext Eval, and Site-Specific Factor 3. If the value of Site-Specific Factor 3 is less than 096 (i.e., prostatectomy was done and extension information is available for staging), the T category is taken from the Site-Specific Factor 3 mapping, and identified as a pT. Otherwise (i.e., Site-Specific Factor 3 code is 096 or greater,

meaning that prostatectomy was not performed, or it was performed but the information is not usable for staging), the T category is taken from the CS Extension mapping, and the c, p, y, or an indicator is taken from the TS/Ext Eval mapping.

Prostate

CS Extension-Clinical Extension

Code	Description	TNM	SS77	SS2000
00	In situ: noninvasive; intraepithelial	Tis	IS	IS
10	Clinically inapparent tumor, number of foci or percent involved tissue not specified Stage A, NOS	T1NOS	L	L
13	Incidental histologic finding in 5% or less of tissue resected (clinically inapparent)	T1a	L	L
14	Incidental histologic finding more than 5% of tissue resected (clinically inapparent)	T1b	L	L
15	Tumor identified by needle biopsy, e.g., for elevated PSA (clinically inapparent)	T1c	L	L
20	Involvement in one lobe, NOS (clinically apparent only)	T2NOS	L	L
21	Involves one half of one lobe or less (clinically apparent only)	T2a	L	L
22	Involves more than one half of one lobe, but not both lobes (clinically apparent only)	T2b	L	L
23	Involves both lobes (clinically apparent only)	T2c	L	L
24	Clinically apparent tumor confined to prostate, NOS Stage B, NOS	T2NOS	L	L
30	Localized, NOS Confined to prostate, NOS Intracapsular involvement only Not stated if Stage A or B, T1 or T2, clinically apparent or inapparent	T2NOS	L	L
31	Into prostatic apex/arising in prostatic apex, NOS	T2NOS	L	L
33	Arising in prostatic apex	T2NOS	L	L
34	Extending into prostatic apex	T2NOS	L	L
41	Extension to periprostatic tissue (Stage C1) Extracapsular extension (beyond prostatic capsule), NOS Through capsule, NOS	T3NOS	RE	RE
42	Unilateral extracapsular extension	T3a	RE	RE
43	Bilateral extracapsular extension	T3a	RE	RE
45	Extension to seminal vesicle(s) (Stage C2)	T3b	RE	RE
49	Periprostatic extension, NOS (Unknown if seminal vesicle(s) involved) Stage C, NOS	T3NOS	RE	RE

50	Extension to or fixation to adjacent structures other than seminal vesicles: Bladder neck Bladder, NOS Fixation, NOS Rectovesical (Denonvillier's) fascia Rectum; external sphincter	T4	RE	RE
52	Levator muscles Skeletal muscle, NOS Ureter(s)	T4	D	RE
60	Extension to or fixation to pelvic wall or pelvic bone "Frozen pelvis", NOS (See Note 5)	T4	D	D
70	Further contiguous extension (Stage D2) including to: Bone Other organs Penis Sigmoid colon Soft tissue other than periprostatic	T4	D	D
95	No evidence of primary tumor	T0	U	U
99	Extension unknown Primary tumor cannot be assessed Not documented in patient record	TX	U	U

Prostate

CS TS/Ext-Eval

Note 1: For this site, use this item to evaluate the coding of tumor size and extension as coded in both CS Extension (clinical for prostate) and Site-Specific Factor 3, Pathologic Extension if prostatectomy was performed.

Note 2: The codes for this item for prostate differ from the codes used for most other sites. AJCC allows pathologic staging to be assigned on the basis of some biopsies without resection. According to the AJCC manual, "In general, total prostatoseminal-vesiculectomy, including regional node specimen, and histologic confirmation are required for pathologic T classification. However, under certain circumstances, pathologic T classification can be determined with other means. For example, (1) positive biopsy of the rectum permits a pT4 classification without prostatoseminal-vesiculectomy, and (2) a biopsy revealing carcinoma in extraprostatic soft tissue permits a pT3 classification, as does a biopsy revealing adenocarcinoma infiltrating the seminal vesicles." (P. 310)

Note 3: For this site, the T category and its associated c, p, y, or a indicator are assigned based on the values in CS Extension, CS TS/Ext Eval, and Site-Specific Factor 3. For details, see Note 7 under CS Extension.

Note 4: According to AJCC, staging basis for transurethral resection of prostate (TURP) is clinical and is recorded as CS TS/Ext-Eval "1" (c).

Code	Description	Staging Basis
0	No surgical resection done. Evaluation based on physical examination, imaging examination, or other non-invasive clinical evidence. No autopsy evidence used.	c
1	No surgical resection done. Evaluation based on endoscopic examination, diagnostic biopsy, including fine needle aspiration biopsy, or other invasive techniques including surgical observation without biopsy. No autopsy evidence used. Does not meet criteria for AJCC pathological T staging.	c
2	No surgical resection done, but positive biopsy of extraprostatic tissue allows assignment to CS Extension Codes [(41) to (70)] (see Note 2)	p

3	No surgical resection done, but evidence derived from autopsy (tumor was suspected or diagnosed prior to autopsy)	p
4	Surgical resection performed WITHOUT pre-surgical systemic treatment or radiation OR surgical resection performed, unknown if pre-surgical systemic treatment or radiation performed. Evidence acquired before treatment, supplemented or modified by the additional evidence acquired during and from surgery, particularly from pathologic examination of the resected specimen. Meets criteria for AJCC pathologic T staging.	p
5	Surgical resection performed WITH pre-surgical systemic treatment or radiation, BUT tumor size/extension based on clinical evidence	c
6	Surgical resection performed WITH pre-surgical systemic treatment or radiation; BUT tumor size/extension based on pathologic evidence	y
8	Evidence from autopsy only (tumor was unsuspected or undiagnosed prior to autopsy)	a
9	Unknown if surgical resection done Not assessed; cannot be assessed Unknown if assessed Not documented in patient record	c

Prostate

CS Lymph Nodes

Note: Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in the field Mets at DX.

Code	Description	TNM	SS77	SS2000
00	None; no regional lymph node involvement	N0	NONE	NONE
10	Regional nodes, including contralateral or bilateral lymph nodes: Iliac, NOS External Internal (hypogastric), NOS: Obturator Pelvic, NOS Periprostatic Sacral, NOS Lateral (laterosacral) Middle (promontorial) (Gerota's node) Presacral Regional lymph node(s), NOS	N1	RN	RN
80	Lymph nodes, NOS	N1	RN	RN
99	Unknown; not stated Regional lymph node(s) cannot be assessed	NX	U	U

Prostate

CS Reg Nodes Eval

SEE STANDARD TABLE

Prostate
Reg LN Pos
SEE STANDARD TABLE

Prostate
Reg LN Exam
SEE STANDARD TABLE

Prostate
CS Mets at DX

Code	Description	TNM	SS77	SS2000
00	No; none	M0	NONE	NONE
11	Distant lymph node(s), NOS Common iliac	M1a	RN	D
12	Distant lymph node(s): Aortic, NOS: Lateral (lumbar) Para-aortic Periaortic Cervical Inguinal, NOS Deep, NOS Node of Coquet or Rosenmuller (highest deep inguinal) Superficial (femoral) Retroperitoneal, NOS Scalene (inferior deep cervical) Supraclavicular (transverse cervical) Distant lymph node(s), NOS	M1a	D	D
30	Metastasis in bone(s)	M1b	D	D
35	(30) + [(11) or (12)]	M1b	D	D
40	Distant metastasis, other than distant lymph node(s) (codes 11 or 12) or bone(s) Carcinomatosis	M1c	D	D
45	Distant metastasis, NOS Stage D2, NOS	M1NOS	D	D
50	(40) + any of [(11) or (12)]	M1c	D	D
55	(40) + any of [(30) or (35)]	M1c	D	D
99	Unknown if distant metastasis Distant metastasis cannot be assessed Not documented in patient record	MX	U	U

Prostate
CS Mets Eval
SEE STANDARD TABLE

Prostate

CS Site-Specific Factor 1 Prostatic Specific Antigen (PSA) Lab Value

Note 1: Record the highest PSA lab value prior to diagnostic biopsy or treatment. For example, a pretreatment PSA of 20.0 ng/ml would be recorded as 200.

Note 2: Lab values for SSFs 1 and 2 should be from the same laboratory test.

Code	Description
000	Test not done (test was not ordered and was not performed)
001	0.1 or less ng/ml (actual value with implied decimal point)
002-899	0.2 - 89.9 ng/ml (actual value with implied decimal point)
990	99.0 or greater ng/ml (actual value with implied decimal point)
999	Unknown or no information Not documented in patient record

Prostate

CS Site-Specific Factor 2 Prostatic Specific Antigen (PSA)

Note 1: Use the highest PSA lab value prior to diagnostic biopsy or treatment.

Note 2: Lab values for SSFs 1 and 2 should be from the same laboratory test.

Code	Description
000	Test not done (test was not ordered and was not performed)
010	Positive/elevated
020	Negative/normal; within normal limits
030	Borderline; undetermined whether positive or negative
080	Ordered, but results not in chart
999	Unknown or no information Not documented in patient record

Prostate

CS Site-Specific Factor 3 CS Extension - Pathologic Extension

Note 1: Include information from prostatectomy in this field and not in CS Extension - Clinical Extension. Use all histologic information including the prostatectomy if it was done within the first course of treatment. Code 097 if there was no prostatectomy performed within the first course of treatment.

Note 2: Limit information in this field to first course of treatment in the absence of disease progression.

Note 3: Involvement of the prostatic urethra does not alter the extension code.

Note 4: When the apical margin, distal urethral margin, bladder base, or bladder neck margin is involved and there is no extracapsular extension, use code 040.

Note 5: When prostate cancer is an incidental finding during a prostatectomy for other reasons (for example, a cystoprostatectomy for bladder cancer), use the appropriate code for the extent of disease found (for example, one lobe, or both lobes, or more).

Note 6: "Frozen pelvis" is a clinical term which means tumor extends to pelvic sidewall(s). In the absence of a more detailed statement of involvement, assign this to code 060.

Note 7: AUA stage. Some of the American Urological Association (AUA) stages A-D are provided as guidelines for coding in the absence of more specific information in the medical record. If physician-assigned AUA stage D1-D2 is based on involvement of lymph nodes only, code under CS Lymph Nodes or CS Mets at DX, not CS Extension - Pathologic Extension

Note 8: For the extension fields for this site, the mapping values for TNM, SS77, and SS2000 and the associated c, p, y, or a indicators are assigned based on the values in CS Extension, CS TS/Ext Eval, and Site-Specific Factor 3. If the value of Site-Specific Factor 3 is less than 096 (i.e., prostatectomy was done and extension information is available for staging), the mapping values are taken from the Site-Specific Factor 3 mapping, and the T category is identified as a pT. Otherwise, (i.e., Site-Specific Factor 3 code is 096 or greater, meaning that prostatectomy was not performed, or it was performed but the information is not usable for staging), the mapping values are taken from the CS Extension mapping, and the c, p, y, or a indicator are taken from the TS/Ext Eval mapping.

Prostate

CS Site-Specific Factor 3 CS Extension

Code	Description	TNM	SS77	SS2000
000	In situ; non-invasive; intraepithelial	Tis	IS	IS
020	Involvement in one lobe, NOS	T2NOS	L	L
021	Involves one half of one lobe or less	T2a	L	L
022	Involves more than one half of one lobe, but not both lobes	T2b	L	L
023	Involves both lobes	T2c	L	L
030	Localized, NOS Confined to prostate, NOS Intracapsular involvement only Stage B, NOS	T2NOS	L	L
031	Into prostatic apex/arising in prostatic apex, NOS (see also codes 033 and 034)	T2NOS	L	L
032	Invasion into (but not beyond) prostatic capsule	T2NOS	L	L
033	Arising in prostatic apex	T2NOS	L	L
034	Extending into prostatic apex	T2NOS	L	L
040	No extracapsular extension but margins involved (See Note 4)	T3NOS	L	RE
041	Extension to periprostatic tissue (Stage C1): Extracapsular extension (beyond prostatic capsule), NOS Through capsule, NOS	T3a	RE	RE
042	Unilateral extracapsular extension	T3a	RE	RE
043	Bilateral extracapsular extension	T3a	RE	RE
045	Extension to seminal vesicle(s) (Stage C2)	T3b	RE	RE
048	Extracapsular extension and margins involved	T3NOS	RE	RE
050	Extension to or fixation to adjacent structures other than seminal vesicles: Bladder neck Bladder, NOS Fixation, NOS Rectovesical (Denonvillier's) fascia Rectum; external sphincter	T4	RE	RE

052	Levator muscle Skeletal muscle, NOS Ureter	T4	D	RE
060	Extension to or fixation to pelvic wall or pelvic bone "Frozen pelvis", NOS (See Note 6)	T4	D	D
070	Further contiguous extension (Stage D2) including to: Bone Penis Sigmoid colon Soft tissue other than periprostatic tissue Other organs	T4	D	D
095	No evidence of primary tumor	T0	U	U
096	Unknown if prostatectomy done	TX	U	U
097	No prostatectomy done within first course of treatment	TX	U	U
098	Prostatectomy was done within first course of treatment, but there was disease progression	TX	U	U
099	Prostatectomy done: Extension unknown Primary tumor cannot be assessed Not documented in patient record	TX	U	U

Prostate

CS Site-Specific Factor 4 Prostatic Acid Phosphatase (PAP)

Code	Description
000	Test not done (test was not ordered and was not performed)
010	Positive/elevated
020	Negative/normal; within normal limits
030	Borderline; undetermined whether positive or negative
080	Ordered, but results not in chart
999	Unknown or no information Not documented in patient record

Prostate

CS Site-Specific Factor 5 Gleason's Primary Pattern and Secondary Pattern Value

Note: If only one number is given and it is less than or equal to 5, assume that it describes a pattern and uses the number as the primary pattern and code the secondary as '9'.

Code	Description
000	Test not done (test was not ordered and was not performed)
011	Primary pattern 1, secondary pattern 1
012	Primary pattern 1, secondary pattern 2
013	Primary pattern 1, secondary pattern 3
014	Primary pattern 1, secondary pattern 4
015	Primary pattern 1, secondary pattern 5
019	Primary pattern 1, secondary pattern 9
021	Primary pattern 2, secondary pattern 1
022	Primary pattern 2, secondary pattern 2
023	Primary pattern 2, secondary pattern 3
024	Primary pattern 2, secondary pattern 4
025	Primary pattern 2, secondary pattern 5
029	Primary pattern 2, secondary pattern unknown
031	Primary pattern 3, secondary pattern 1
032	Primary pattern 3, secondary pattern 2
033	Primary pattern 3, secondary pattern 3
034	Primary pattern 3, secondary pattern 4
035	Primary pattern 3, secondary pattern 5
039	Primary pattern 3, secondary pattern unknown
041	Primary pattern 4, secondary pattern 1
042	Primary pattern 4, secondary pattern 2
043	Primary pattern 4, secondary pattern 3
044	Primary pattern 4, secondary pattern 4
045	Primary pattern 4, secondary pattern 5
049	Primary pattern 4, secondary pattern unknown
051	Primary pattern 5, secondary pattern 1
052	Primary pattern 5, secondary pattern 2
053	Primary pattern 5, secondary pattern 3

054	Primary pattern 5, secondary pattern 4
055	Primary pattern 5, secondary pattern 5
059	Primary pattern 5, secondary pattern unknown
099	Primary pattern unknown
999	Unknown or no information Not documented in patient record

Prostate

CS Site-Specific Factor 6 Gleason's Score

Note 1: Usually prostate cancers are graded using Gleason's score or pattern. Gleason's grading for prostate primaries is based on a 5-component system (5 histologic patterns). Prostatic cancer generally shows two main histologic patterns. The primary pattern—that is, the pattern occupying greater than 50% of the cancer—is usually indicated by the first number of the Gleason's grade, and the secondary pattern is usually indicated by the second number. These two numbers are added together to create a pattern score, ranging from 2 to 10. If the pathologist gives only one number and it is less than or equal to 5, assume that it describes a pattern. If only one number is given and it is greater than 5, assume that it is a score. If there are two numbers, assume that they refer to two patterns (the first number being the primary and the second number being the secondary) and sum them to obtain the score.

Note 2: Record the Gleason's score based on the addition of the primary and secondary pattern.

Code	Description
000	Test not done (test was not ordered and was not performed)
002-010	Gleason's Score (See Notes 1 and 2)
999	Unknown or no information Not documented in patient record

Collaborative Staging Codes

Testis

C62.0-C62.1, C62.9

C62.0 Undescended testis

C62.1 Descended testis

C62.9 Testis, NOS

CS Tumor Size	CS Site-Specific Factor 1 - Alpha Fetoprotein (AFP)	The following tables are available at the collaborative staging website: Histology Exclusion Table AJCC Stage Serum Marker S Value Table Extension Orchiectomy Table Number Positive Lymph Nodes and Size of Metastasis in Lymph Nodes
CS Extension	CS Site-Specific Factor 2 - Human chorionic gonadotropin (hCG)	
CS TS/Ext-Eval	CS Site-Specific Factor 3 - LDH	
CS Lymph Nodes	CS Site-Specific Factor 4 - Radical Orchiectomy Performed	
CS Reg Nodes Eval	CS Site-Specific Factor 5 - Size of Metastasis in Lymph Nodes	
Reg LN Pos	CS Site-Specific Factor 6	
Reg LN Exam		
CS Mets at DX		
CS Mets Eval		

Testis

CS Tumor Size

SEE STANDARD TABLE

Testis

CS Extension

Note 1: Laterality must be coded for this site.

Note 2: According to AJCC, "Except for pTis and pT4, extent of primary tumor for TNM is classified by radical orchiectomy. TX is used for other categories in the absence of radical orchiectomy." For Collaborative Staging, this means that the categories of T1, T2, and T3 are derived only when Site Specific Factor 4 indicates that a radical orchiectomy was performed. See the Extension Orchiectomy table for details.

Code	Description	TNM	SS77	SS2000
00	In situ: noninvasive; intraepithelial Intratubular germ cell neoplasia	Tis	IS	IS
10	Invasive tumor WITHOUT vascular/lymphatic invasion, or presence of vascular/lymphatic invasion or NOS Body of testis Rete testis Tunica albuginea	*	L	L
15	Invasive tumor WITH vascular/lymphatic invasion Body of testis Rete testis Tunica albuginea	*	L	L
20	Tunica vaginalis involved Surface implants	*	L	L
30	Localized, NOS	*	L	L
31	Tunica, NOS	TX	L	L
40	Epididymis involved WITHOUT vascular/lymphatic invasion, or presence of vascular/lymphatic invasion not stated	*	RE	RE

45	Epididymis involved WITH vascular/lymphatic invasion	*	RE	RE
50	Spermatic cord, ipsilateral Vas deferens	*	RE	RE
60	Dartos muscle, ipsilateral Scrotum, ipsilateral	T4	RE	RE
70	Extension to scrotum, contralateral Ulceration of scrotum	T4	D	D
75	Penis	T4	D	D
80	Further contiguous extension	T4	D	D
95	No evidence of primary tumor	T0	U	U
99	Unknown extension Primary tumor cannot be assessed Not documented in patient record	TX	U	U

* For extension codes 10, 15, 20, 30, 40, 45, and 50, the T category is assigned based on the values of CS Extension and Site-Specific Factor 4 (Radical Orchiectomy Performed), using the Extension/Orchiectomy extra table.

Testis

CS TS/Ext-Eval

SEE STANDARD TABLE

Testis

CS Lymph Nodes

Note 1: Regional nodes in codes 10-30 include contralateral and bilateral nodes.

Note 2: Involvement of inguinal, pelvic, or external iliac lymph nodes in the absence of previous scrotal or inguinal surgery is coded in CS Mets at DX, as distant lymph node involvement.

Code	Description	TNM	SS77	SS2000
00	No regional lymph node involvement	N0	NONE	NONE
10	Regional lymph node(s) (bilateral and contralateral): Aortic, NOS: Lateral (lumbar) Para-aortic Periaortic Preaortic Retroaortic Retroperitoneal, NOS Spermatic vein Regional lymph node(s), NOS	*	RN	RN
20	Regional lymph node(s) (bilateral and contralateral): Pericaval, NOS: Interaortocaval Paracaval Precaval Retrocaval	*	D	RN

30	Regional lymph node(s) (bilateral and contralateral): Pelvic, NOS External iliac WITH previous scrotal or inguinal surgery	*	RN	RN
40	Inguinal nodes, NOS: Deep, NOS Node of Cloquet or Rosenmuller (highest deep inguinal) Superficial (femoral) WITH previous scrotal or inguinal surgery	*	D	D
50	Regional lymph node(s), NOS	*	RN	RN
80	Lymph nodes, NOS	*	RN	RN
99	Unknown; not stated Regional lymph node(s) cannot be assessed Not documented in patient record	NX	U	U

* For codes 10, 20, 30, 40, 50, and 80 the N category is assigned from the Number Positive Lymph Nodes and Size of Metastasis in Lymph Nodes extra table using the values of Site Specific Factor 5 (Size of Metastasis in Lymph Nodes) and Reg LN Pos.

Testis

CS Reg Nodes Eval

SEE STANDARD TABLE

Testis

Reg LN Pos

SEE STANDARD TABLE

Testis

Reg LN Exam

SEE STANDARD TABLE

Testis

CS Mets at DX

Note: Involvement of inguinal, pelvic, or external iliac lymph nodes after previous scrotal or inguinal surgery is coded under CS Lymph Nodes, as regional node involvement.

Code	Description	TNM	SS77	SS2000
00	No; none	M0	NONE	NONE
11	Distant lymph node(s): Pelvic, NOS External iliac WITHOUT previous scrotal or inguinal surgery, or unknown if previous scrotal or inguinal surgery	M1a	RN	RN

12	Distant lymph node(s): Inguinal nodes, NOS: Deep, NOS Node of Cloquet or Rosenmuller (highest deep inguinal) Superficial (femoral) WITHOUT previous scrotal or inguinal surgery, or unknown if previous scrotal or inguinal surgery	M1a	D	D
13	Specified distant lymph node(s), other than code (11) or (12) Distant lymph node(s), NOS	M1a	D	D
20	Distant metastasis to lung	M1a	D	D
25	Distant metastases to lung and lymph node(s) (20) + any of [(11) to (13)]	M1a	D	D
40	Metastasis to other distant sites (WITH or WITHOUT metastasis to lung and/or distant lymph node(s)) Carcinomatosis	M1b	D	D
45	Distant metastasis, NOS	MINOS	D	D
99	Unknown Distant metastasis cannot be assessed Not documented in patient record	MX	U	U

Testis

CS Mets Eval

SEE STANDARD TABLE

Testis

CS Site-Specific Factor 1 Alpha Fetoprotein (AFP)

Code	Description
000	Test not done (SX)
020	Within normal limits (S0)
040	Range 1 (S1) less than 1,000 ng/ml
050	Range 2 (S2) 1,000 -10,000 ng/ml
060	Range 3 (S3) greater than 10,000 ng/ml
080	Ordered, but results not in chart
999	Unknown or no information Not documented in patient record

Testis

CS Site-Specific Factor 2 Human Chorionic Gonadotropin (hCG)

Code	Description
000	Test not done (SX)

020	Within normal limits (S0)
040	Range 1 (S1) less than 5,000 mIU/ml
050	Range 2 (S2) 5,000 - 50,000 mIU/ml
060	Range 3 (S3) greater than 50,000 mIU/ml
080	Ordered, but results not in chart
999	Unknown or no information Not documented in patient record

Testis

CS Site-Specific Factor 3 LDH (Lactate Dehydrogenase)

Code	Description
000	Test not done (SX)
020	Within normal limits (S0)
040	Range 1 (S1) 1.5 x N (N equals the upper limit of normal for LDH)
050	Range 2 (S2) 1.5 - 10 x N (N equals the upper limit of normal for LDH)
060	Range 3 (S3) greater than 10 x N (N equals the upper limit of normal for LDH)
080	Ordered, but results not in chart
999	Unknown or no information Not documented in patient record

Testis

CS Site-Specific Factor 4 Radical Orchiectomy Performed

Code	Description
000	Radical orchiectomy not performed
001	Radical orchiectomy performed
999	Unknown if radical orchiectomy performed

Testis

CS Site-Specific Factor 5 Size of Metastasis in Lymph Nodes

Note: For CS Lymph Nodes codes 10, 20, 30, 40 and 50, the N category is assigned based on the values in the Site Specific Factor 5 Table below and the Number Lymph Nodes Positive and Size of Lymph Node Metastasis Extra Table.

Code	Description
000	No lymph node metastasis
001	Lymph node metastasis mass 2 cm or less in greatest dimension No extranodal extension of tumor
002	Lymph node metastasis mass more than 2 cm but not more than 5 cm in greatest dimension Extranodal extension of tumor

003	Lymph node metastasis mass more than 5 cm in greatest dimension
998	Regional lymph node(s) involved, size of lymph node mass, number of positive lymph nodes and extranodal extension status not stated
999	Unknown if regional nodes involved Not documented in patient record

Testis

CS Site-Specific Factor 6

Code	Description
888	Not applicable for this site

Collaborative Staging Codes

Other and Unspecified Male Genital Organs (excluding: Kaposi Sarcoma and Lymphoma)

C63.0-C63.1, C63.7-C63.9

C63.0 Epididymis

C63.1 Spermatic cord

C63.7 Other specified parts of male genital organs

C63.8 Overlapping lesion of male genital organs

C63.9 Male genital organs, NOS

Note 1: AJCC does not define TNM staging for this site.

Note 2: Laterality must be coded for C63.0-C63.1.

Note 3: Carcinoma of the scrotum is included in the scrotum schema. Melanoma (M-8720-8790) of scrotum is included in the melanoma skin schema. Mycosis fungoides (M-9700) or Sezary disease (M-9701) of scrotum is included in the mycosis fungoides schema. Melanoma, mycosis fungoides, or Sezary disease of any other site listed is coded using this schema. Kaposi sarcoma of all sites is included in the Kaposi sarcoma schema, and lymphomas of all sites are included in the lymphoma schema.

CS Tumor Size	CS Site-Specific Factor 1	The following tables are available at the collaborative staging website: Histologies for Which AJCC Staging Is Not Generated AJCC Stage
CS Extension	CS Site-Specific Factor 2	
CS TS/Ext-Eval	CS Site-Specific Factor 3	
CS Lymph Nodes	CS Site-Specific Factor 4	
CS Reg Nodes Eval	CS Site-Specific Factor 5	
Reg LN Pos	CS Site-Specific Factor 6	
Reg LN Exam		
CS Mets at DX		
CS Mets Eval		

Other and Unspecified Male Genital Organs (excluding: Kaposi Sarcoma and Lymphoma)

CS Tumor Size

SEE STANDARD TABLE

Other and Unspecified Male Genital Organs (excluding: Kaposi Sarcoma and Lymphoma)

CS Extension

Code	Description	TNM	SS77	SS2000
00	In situ: noninvasive; intraepithelial	NA	IS	IS
10	Confined to site of origin	NA	L	L
30	Localized, NOS	NA	L	L
40	Adjacent connective tissue (See definition of connective tissue in the general instructions)	NA	RE	RE
60	Adjacent organs/structures: Male genital organs: Penis Prostate Testis Sites in this schema which are not the primary	NA	RE	RE
80	Further contiguous extension Other organs and structures in male pelvis: Bladder Rectum Urethra	NA	D	D

95	No evidence of primary tumor	NA	U	U
99	Unknown extension Primary tumor cannot be assessed Not documented in patient record	NA	U	U

Other and Unspecified Male Genital Organs (excluding: Kaposi Sarcoma and Lymphoma)

CS TS/Ext-Eval

Code	Description	Staging Basis
9	Not applicable for this site	NA

Other and Unspecified Male Genital Organs (excluding: Kaposi Sarcoma and Lymphoma)

CS Lymph Nodes

Note: Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in the field Mets at DX.

Code	Description	TNM	SS77	SS2000
00	None; no regional lymph node involvement	NA	NONE	NONE
10	Regional lymph node(s) Iliac, NOS: External Internal (hypogastric), NOS: Obturator Inguinal, NOS: Deep inguinal, NOS: Node of Cloquet or Rosenmuller (highest deep inguinal) Superficial inguinal (femoral) Pelvic, NOS Regional lymph node(s), NOS	NA	RN	RN
80	Lymph nodes, NOS	NA	RN	RN
99	Unknown; not stated Regional lymph node(s) cannot be assessed	NA	U	U

Other and Unspecified Male Genital Organs (excluding: Kaposi Sarcoma and Lymphoma)

CS Reg Nodes Eval

Code	Description	Staging Basis
9	Not applicable for this site	NA

Other and Unspecified Male Genital Organs (excluding: Kaposi Sarcoma and Lymphoma)
Reg LN Pos
SEE STANDARD TABLE

Other and Unspecified Male Genital Organs (excluding: Kaposi Sarcoma and Lymphoma)
Reg LN Exam
SEE STANDARD TABLE

Other and Unspecified Male Genital Organs (excluding: Kaposi Sarcoma and Lymphoma)
CS Mets at DX

Code	Description	TNM	SS77	SS2000
00	No; none	NA	NONE	NONE
10	Distant lymph node(s), NOS	NA	D	D
40	Distant metastases except distant lymph node(s) (code 10) Distant metastasis, NOS Carcinomatosis	NA	D	D
50	(10) + (40) Distant lymph node(s) plus other distant metastases	NA	D	D
99	Unknown if distant metastasis Cannot be assessed Not documented in patient record	NA	U	U

Other and Unspecified Male Genital Organs (excluding: Kaposi Sarcoma and Lymphoma)
CS Mets Eval

Code	Description	Staging Basis
9	Not applicable for this site	NA

Other and Unspecified Male Genital Organs (excluding: Kaposi Sarcoma and Lymphoma)
CS Site-Specific Factor 1

Code	Description
888	Not applicable for this site

Other and Unspecified Male Genital Organs (excluding: Kaposi Sarcoma and Lymphoma)
CS Site-Specific Factor 2

Code	Description
888	Not applicable for this site

**Other and Unspecified Male Genital Organs (excluding: Kaposi Sarcoma and Lymphoma)
CS Site-Specific Factor 3**

Code	Description
888	Not applicable for this site

**Other and Unspecified Male Genital Organs (excluding: Kaposi Sarcoma and Lymphoma)
CS Site-Specific Factor 4**

Code	Description
888	Not applicable for this site

**Other and Unspecified Male Genital Organs (excluding: Kaposi Sarcoma and Lymphoma)
CS Site-Specific Factor 5**

Code	Description
888	Not applicable for this site

**Other and Unspecified Male Genital Organs (excluding: Kaposi Sarcoma and Lymphoma)
CS Site-Specific Factor 6**

Code	Description
888	Not applicable for this site

Collaborative Staging Codes

Scrotum [excl. Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease, and Other Lymphomas]

C63.2 Scrotum, NOS

Note: Melanoma (M-8720-8790) of scrotum is included in the melanoma schema. Mycosis Fungoides (M-9700) or Sezary disease (M-9701) of scrotum is included in the Mycosis Fungoides schema. Kaposi sarcoma of the scrotum is included in the Kaposi Sarcoma schema. Lymphoma of the scrotum is included in the lymphoma schema.

CS Tumor Size	CS Site-Specific Factor 1	The following tables are available at the collaborative staging website: Histology Exclusion Table AJCC Stage Extension Size Table
CS Extension	CS Site-Specific Factor 2	
CS TS/Ext-Eval	CS Site-Specific Factor 3	
CS Lymph Nodes	CS Site-Specific Factor 4	
CS Reg Nodes Eval	CS Site-Specific Factor 5	
Reg LN Pos	CS Site-Specific Factor 6	
Reg LN Exam		
CS Mets at DX		
CS Mets Eval		

Scrotum [excl. Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease, and Other Lymphomas]

CS Tumor Size

SEE STANDARD TABLE

Scrotum [excl. Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease, and Other Lymphomas]

CS Extension

Code	Description	TNM	SS77	SS2000
00	In situ; noninvasive; intraepidermal	Tis	IS	IS
10	Confined to scrotum	*	L	L
30	Localized, NOS	*	L	L
40	Adjacent connective tissue (See definition of connective tissue in general instructions)	*	RE	RE
60	Adjacent organs/structures Male genital organs: Epididymis Penis Prostate Spermatic cord Testis	T4	RE	RE
80	Further contiguous extension Other organs and structures in male pelvis: Bladder Rectum Urethra	T4	D	D

95	No evidence of primary tumor	T0	U	U
99	Unknown extension Primary tumor cannot be assessed Not documented in patient record	TX	U	U

* For CS Extension codes 10, 30 and 40 ONLY, the T category is assigned based on the value of CS Tumor Size, as shown in the Extension Size table for this site.

Scrotum [excl. Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease, and Other Lymphomas]

CS TS/Ext-Eval

SEE STANDARD TABLE

Scrotum [excl. Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease, and Other Lymphomas]

CS Lymph Nodes

Note: Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in the field Mets at DX.

Code	Description	TNM	SS77	SS2000
00	None; no regional lymph node involvement	N0	NONE	NONE
10	Regional lymph nodes Iliac, NOS: External Internal (hypogastric), NOS: Obturator Inguinal, NOS: Deep inguinal, NOS Node of Cloquet or Rosenmuller (highest deep inguinal) Superficial inguinal (femoral) Regional lymph node(s), NOS	N1	RN	RN
80	Lymph nodes, NOS	N1	RN	RN
99	Unknown; not stated Regional lymph node(s) cannot be assessed Not documented in patient record	NX	U	U

Scrotum [excl. Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease, and Other Lymphomas]

CS Reg Nodes Eval

SEE STANDARD TABLE

Scrotum [excl. Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease, and Other Lymphomas]

Reg LN Pos

SEE STANDARD TABLE

Scrotum [excl. Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease, and Other Lymphomas]

Reg LN Exam

SEE STANDARD TABLE

Scrotum [excl. Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease, and Other Lymphomas]

CS Mets at DX

SEE STANDARD TABLE

Scrotum [excl. Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease, and Other Lymphomas]

CS Mets Eval

SEE STANDARD TABLE

Scrotum [excl. Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease, and Other Lymphomas]

CS Site-Specific Factor 1

Code	Description
888	Not applicable for this site

Scrotum [excl. Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease, and Other Lymphomas]

CS Site-Specific Factor 2

Code	Description
888	Not applicable for this site

Scrotum [excl. Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease, and Other Lymphomas]

CS Site-Specific Factor 3

Code	Description
888	Not applicable for this site

Scrotum [excl. Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease, and Other Lymphomas]

CS Site-Specific Factor 4

Code	Description
888	Not applicable for this site

Scrotum [excl. Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease, and Other Lymphomas]

CS Site-Specific Factor 5

Code	Description
888	Not applicable for this site

**Scrotum [excl. Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease,
and Other Lymphomas]
CS Site-Specific Factor 6**

Code	Description
888	Not applicable for this site